Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International

Wikipedia Affiliate Button

Home > Press > Arrowhead Pharmaceuticals to Participate in Upcoming September 2019 Conferences

Abstract:
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:

Arrowhead Pharmaceuticals to Participate in Upcoming September 2019 Conferences

Pasadena. CA | Posted on August 30th, 2019

Baird's 2019 Global Healthcare Conference – New York, September 4-5, 2019

September 4, 9:40 a.m. EDT –Chris Anzalone, Ph.D., Arrowhead’s president and CEO, will deliver a corporate presentation

Citi’s 14th Annual Biotech Conference– Boston, September 5, 2019

Global Summit on Cardiology and Heart Diseases – Dubai, UAE, September 16-17, 2019

September 16, 11:00 a.m. GST –Bruce Given, M.D., Arrowhead’s chief operating officer and head of R&D, will deliver a keynote presentation titled, “Treating hypertriglyceridemic states with RNA interference – emergence of an exciting new modality to treat cardiovascular diseases”

A copy of the presentation materials and webcast links, if the presentation is being webcast, may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.

####

About Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.

For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts .

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the safety and efficacy of our product candidates, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

For more information, please click here

Contacts:
Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400


Investors and Media:
LifeSci Advisors, LLC
Brian Ritchie
212-915-2578

www.lifesciadvisors.com

Copyright © Arrowhead Pharmaceuticals, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanomedicine

Novel formulation permits use of toxin from rattlesnake venom to treat chronic pain: Researchers Butantan Institute succeeded in reducing the toxicity and potentiating the analgesic effect of crotoxin by encapsulating it in nanostructured silica -- the results of tests in an anim February 14th, 2020

Gold nanoclusters: new frontier for developing medication for treatment of Alzheimer's disease February 14th, 2020

Nanotech company granted FDA Fast Track for treatment of head & neck cancer February 10th, 2020

Arrowhead Reports Interim Clinical Data on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3 February 5th, 2020

Announcements

CEA-Leti and CEA-IRIG Demonstrate Quantum Integrated Circuit Combining Quantum Dot with Digital-Analog Circuits on CMOS Chip: Presentation at ISSCC 2020 Shows Role FD-SOI Can Play in Embedding Qubit Arrays with Classic Electronics to Build Large-Scale Quantum Silicon Processors February 20th, 2020

CEA-Leti Presents High-Performance Processor Breakthrough With Active Interposer and 3D Stacked Chiplets at ISSCC 2020 February 19th, 2020

New green technology from UMass Amherst generates electricity 'out of thin air' Renewable device could help mitigate climate change, power medical devices February 17th, 2020

KIST unveils the mystery of van der Waals magnets, a material for future semiconductors: Overcoming the limits of current magnetic materials, giving hope for development of next-generation semiconductors February 14th, 2020

Events/Classes

CEA-Leti and CEA-IRIG Demonstrate Quantum Integrated Circuit Combining Quantum Dot with Digital-Analog Circuits on CMOS Chip: Presentation at ISSCC 2020 Shows Role FD-SOI Can Play in Embedding Qubit Arrays with Classic Electronics to Build Large-Scale Quantum Silicon Processors February 20th, 2020

CEA-Leti Presents High-Performance Processor Breakthrough With Active Interposer and 3D Stacked Chiplets at ISSCC 2020 February 19th, 2020

CEA-Leti Clears a Path to Developing Ultralow Loss, High-Power Photonics in UV through Mid-Infrared Wavelengths ‘Breakthrough Will Lead to Quantum Computing, Imaging, Sensing, Communication, and Clocks’ February 3rd, 2020

SUNY Poly Professor Partners with Leading Institutions on NSF Award for Quantum Information Science Research: SUNY Poly Research Builds Upon Recent Quantum-related Research Initiatives and Workshops January 27th, 2020

Nanobiotechnology

Novel formulation permits use of toxin from rattlesnake venom to treat chronic pain: Researchers Butantan Institute succeeded in reducing the toxicity and potentiating the analgesic effect of crotoxin by encapsulating it in nanostructured silica -- the results of tests in an anim February 14th, 2020

Gold nanoclusters: new frontier for developing medication for treatment of Alzheimer's disease February 14th, 2020

Nanotech company granted FDA Fast Track for treatment of head & neck cancer February 10th, 2020

Arrowhead Reports Interim Clinical Data on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3 February 5th, 2020

New-Contracts/Sales/Customers

Oxford Instruments Supplies HLJ Technology Co. Ltd., with Plasma Etch and Deposition Solutions for the fabrication of VCSELS on 6 inch wafers October 3rd, 2019

Toppan Photomasks and GLOBALFOUNDRIES Enter into Multi-Year Supply Agreement August 15th, 2019

180 Degree Capital Corp.’s Portfolio Company, TheStreet, Inc., Enters into Agreement to be Acquired by TheMaven, Inc. for $16.5 Million June 13th, 2019

Analog Bits and GLOBALFOUNDRIES Deliver Differentiated Analog and Mixed Signal IP for High-Performance Mobile and Compute Applications: Analog Bits’ Analog and Mixed Signal IPs Including Various PLLs, PCIe Reference Clock, Sensors and Power Circuits with GLOBALFOUNDRIES 12nm Fin June 5th, 2019

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project